← SynDRA
AVUTOMETINIB
SynDRA canonical compound SYN0038010 — structure-anchored drug synonym record
| Clinical phase | Phase 1 |
|---|
| Primary target(s) | BRAF | MAP2K1 | MAP2K2 | RAF1 |
|---|
| Mechanism of action | MEK inhibitor | RAF inhibitor |
|---|
All known targets
- MAP2K1
- MAP2K2
- RAF1
- ARAF; BRAF; RAF1
- BRAF
Mechanisms of action (all sources)
- MAP2K1 INHIBITOR
- Dual specificity mitogen-activated protein kinase kinase 1 inhibitor
- MAP2K2 INHIBITOR
- Dual specificity mitogen-activated protein kinase kinase 2 inhibitor
- RAF1 INHIBITOR
- MEK inhibitor
- RAF inhibitor
- Modulator
Cross-references
Synonyms
- Rg-7304
- Ro-5126766
- CH-5126766
- CH5126766
- CKI-27
- R-7304
- VS-6766
- RO-5126766
- Dual Raf/MEK protein kinase inhibitor (cancer), Roche
- RO5126766
- Ro 5126766
- VS 6766
- RG 7304
- CHEBI:78825
- D0D4252V97
- RefChem:115811
- Raf/MEK Inhibitor VS-6766
- VS6766
- RG7304
- Ro 5126766 - Bio-X
- RO-5126766 free base
- RO5126766(CH5126766)
- RO5126766 (CH5126766)
- 3wig
- CHU
- Avutometinib [WHO-DD]
- Avutometinib (USAN/INN)
- AVUTOMETINIB [INN]
- AVUTOMETINIB [USAN]
- SCHEMBL960093
- orb1300300
- SCHEMBL29358292
- SCHEMBL29360048
- SCHEMBL29515377
- UNII-D0D4252V97
- GTPL11867
- GLXC-07174
- EX-A2151
- BDBM50010462
Look up AVUTOMETINIB in the interactive SynDRA portal →